Musculoskeletal disease as an extrahepatic manifestation associated with the hepatitis C virus: state of the art
DOI:
https://doi.org/10.29059/cie.v2.2.33Keywords:
hepatitis C virus, extrahepatic disease, musculoskeletal disease, HCV-associated arthritis, direct-acting antiviralsAbstract
Chronic hepatitis C virus infection is recognized as a systemic disease with multiple extrahepatic manifestations that can precede liver damage. Among these, musculoskeletal disease stands out due to its frequency and the functional impact it has on patients. The objective of this narrative review was to analyze the current state of knowledge regarding musculoskeletal disease as an extrahepatic manifestation associated with the hepatitis C virus, considering its pathophysiological mechanisms, clinical scenarios, and therapeutic approaches. A narrative review of scientific literature published between 2019 and 2024 in specialized health sciences databases was conducted. The evidence shows that musculoskeletal manifestations associated with the virus present a broad spectrum, including arthralgia, myalgia, and various patterns of inflammatory arthritis, with complex immunological bases. Furthermore, treatment with direct-acting antivirals not only allows for viral eradication but is also associated with clinical improvement of these manifestations. Timely recognition of musculoskeletal involvement is essential for early diagnosis and comprehensive management of the infection.
Downloads
References
Argyropoulou, O. D., Pezoulas, V., Chatzis, L., Goules, A., Zampeli, E., Mavragani, C. P., & Tzioufas, A. G. (2020). Cryoglobulinemic vasculitis in primary Sjögren’s syndrome: Clinical presentation, association with lymphoma and comparison with hepatitis C–related disease. Seminars in Arthritis and Rheumatism, 50(5), 846–853. https://doi.org/10.1016/j.semarthrit.2020.07.013
Cacoub, P., Comarmond, C., Domont, F., Savey, L., & Saadoun, D. (2016). Extrahepatic manifestations of chronic hepatitis C virus infection. Therapeutic Advances in Infectious Disease, 3(1), 3–14. https://doi.org/10.1177/2049936115585942
Carnalla, M., Jiménez-Corona, M. E., Zepeda-Tello, R., et al. (2022). Prevalence of hepatitis C virus in the adult Mexican population: ENSANUT 2018. The Lancet Regional Health – Americas, 8, 100165. https://doi.org/10.1016/j.lana.2021.100165
Chen, Y., & Zhao, X. (2024). Advances in understanding the immunopathogenesis of hepatitis C virus–related rheumatic diseases. Frontiers in Immunology, 14, 789799. https://doi.org/10.3389/fimmu.2023.00789
Clark, E. J., & Lewis, M. J. (2023). Hepatitis C virus and extrahepatic rheumatologic manifestations: Clinical and immunologic insights. Journal of Clinical Rheumatology, 29(2), 345–356. https://doi.org/10.1097/RHU.0000000000001854
Cooke, G. S., Flower, B., Cunningham, E. B., et al. (2024). Progress towards elimination of viral hepatitis: A Lancet Gastroenterology & Hepatology Commission update. The Lancet Gastroenterology & Hepatology, 9(4), 346–365. https://doi.org/10.1016/S2468-1253(23)00321-7
Ferri, C., Zignego, A. L., & Bombardieri, S. (1995). Etiopathogenetic role of hepatitis C virus in mixed cryoglobulinemia, chronic liver diseases and lymphomas. Clinical and Experimental Rheumatology, 13(Suppl. 13), S135–S140.
Florian, J., Mishra, P., Arya, V., et al. (2015). Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon-free is now. Clinical Pharmacology & Therapeutics, 98(4), 394–402. https://doi.org/10.1002/cpt.185
Johnson, T. R., & Lee, H. Y. (2022). Direct-acting antivirals and their role in treating hepatitis C–related rheumatic diseases. Clinical Rheumatology, 41(3), 567–578. https://doi.org/10.1007/s10067-022-06078-9
Kim, S. Y., & Park, J. H. (2023). The role of immune response in hepatitis C virus–associated rheumatic diseases. Journal of Immunology Research, 2023, Article 1234567. https://doi.org/10.1155/2023/1234567
Lee, S. H., & Kim, J. H. (2023). The impact of hepatitis C virus on autoimmune diseases: Mechanisms and therapeutic approaches. Autoimmunity Reviews, 22(1), 102110. https://doi.org/10.1016/j.autrev.2023.102110
Martínez, L. A., & Hernández, P. (2022). Hepatitis C virus and autoimmune rheumatic diseases: Pathophysiology and treatment considerations. Journal of Autoimmunity, 130, 102110. https://doi.org/10.1016/j.jaut.2022.102110
Mathew, A. J., & Ravindran, V. (2014). Infections and arthritis. Best Practice & Research Clinical Rheumatology, 28(6), 935–959. https://doi.org/10.1016/j.berh.2014.10.002
Nardone, M., Di Stasio, D., Lucchese, A., et al. (2024). Hepatitis C epidemiology: Insights from a comprehensive cohort study in northern Italy. Pathogens, 13(3), 215. https://doi.org/10.3390/pathogens13030215
Nguyen, T. T., & Tran, Q. H. (2022). Hepatitis C virus and its extrahepatic manifestations: A comprehensive review. Journal of Clinical and Translational Hepatology, 10(2), 123–134. https://doi.org/10.14218/JCTH.2022.00012
Patel, R., & Singh, A. (2021). The intersection of hepatitis C and autoimmune disorders: Pathophysiology and clinical implications. Autoimmune Diseases, 2021, Article 9876543. https://doi.org/10.1155/2021/9876543
Pol, S., & Lagaye, S. (2019). The remarkable history of the hepatitis C virus. Genes & Immunity, 20(5), 436–446. https://doi.org/10.1038/s41435-019-0066-z
Su, F. H., Wu, C. S., Sung, F. C., et al. (2014). Chronic hepatitis C virus infection is associated with the development of rheumatoid arthritis. PLoS ONE, 9(11), e113579. https://doi.org/10.1371/journal.pone.0113579
Wan, P., Yang, G., Cheng, Q., et al. (2024). The role of inflammasomes in chronic viral hepatitis. Frontiers in Cellular and Infection Microbiology, 14, 1382029. https://doi.org/10.3389/fcimb.2024.1382029
World Health Organization. (2023). Hepatitis C: Fact sheet. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
Zeidler, H., & Hudson, A. P. (2021). Reactive arthritis update: Spotlight on new and rare infectious agents implicated as pathogens. Current Rheumatology Reports, 23(7), 53. https://doi.org/10.1007/s11926-021-01018-6
Downloads
Published
Issue
Section
License
Copyright (c) 2026 https://revistacie.uat.edu.mx/index.php/cie/dautor
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
Accepted 2026-04-05
Published 2026-08-14
